BUZZ-Kardigan on track to open higher in Nasdaq debut after upsized $400 million IPO

Kardigan

Kardigan

KARD

0.00

** Heart drug developer Kardigan KARD.O on track to open above offer price in Nasdaq debut after $400 million IPO

** Stock recently indicated to open at $21 apiece vs $16 offer price

** KARD sold 25 million shares in an upsized IPO at top end of marketed range of $14 and $16 each

** Biotech IPOs have made a strong comeback this year after a tepid 2025, with a string of sizable offerings pricing over the past two months

** KARD is developing medicines targeting root cause of specific cardiovascular diseases

** It is advancing three late-stage experimental cardiovascular therapies - danicamtiv, ataciguat and tonlamarsen

** J.P. Morgan Securities, Jefferies, Leerink Partners , and TD Securities were underwriters for offering


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.